Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 23, 2019- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
-
Jan 14, 2019* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
-
Jan 9, 2019-HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression
-
Nov 11, 2018* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Nov 7, 2018* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
-
Oct 19, 2018-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype